INSUFICIENCIA CARDIACA                                                                                                 ISSN 1850-1044

Insuf Card 2016;11 (3): 115-121                                                                                           2016 Silver Rose

Pulmonary arterial hypertension in adult congenital heart disease

Impact and outcome

Data from GUTI-GUCH registry

Claudio Gabriel Morós, Marisa Pacheco Otero, Gianina Faliva, Maria del Carmen Rubio, Mariana López Daneri, Isabel Torres, Inés Abella, Alvaro Sosa Liprandi, Liliana Noemí Nicolosi, Maria Grippo

Introduction

Adult congenital heart disease (ACHD) is one of the fastest growing cardiology subgroups in recent years due to the early diagnostics and advance in surgical and endovascular treatment. It is estimated that 85-90% of patients with congenital heart disease will reach adulthood. The survival of these patients generates complications and sequelae which cause a great number of hospitalizations and new surgeries, among other procedures.

It is estimated that 5 – 10% of ACHD patients will develop pulmonary hypertension (PH) during development, being in reality the most frequent cause for pulmonary arterial hypertension (PAH) after connective tissue diseases. Its presence is related to a worst patient’s prognosis.

This work objective was to analyze the epidemiologic characteristics and clinical and pharmacological treatment of patients with PAH and their impact on survival.

Pulmonary arterial hypertension in adult congenital heart disease

Impact and Outcome

Data from the GUTI-GUCH Registry

Claudio Gabriel Morós, Marisa Pacheco Otero, Gianina Faliya, María del Carmen Rubio, Mariana López Daneri, Isabel Torres, Ines Abella, Álvaro Sosa Lipandri, Liliana Noemí Nicolosi, María Grippo.

Introduction

 Adult congenital heart disease (ACHD) is one of the fastest growing cardiology subgroups in recent years, due to early diagnosis and advances in surgical and endovascular treatment. It is estimated that between 85-90% of the congenital heart disease patients will reach adulthood. The survival of these patients generates complications and sequels that result in a higher rate of hospitalizations and new surgeries, among other procedures.

It is estimated that between from 5% to 10% of patients with AHCD will develop pulmonary hypertension (PH) during their evolution being nowadays the most frequent cause of pulmonary arterial hypertension (PAH) after the connective tissue diseases. Its presence it is related with the worst patient’s prognosis.

The present work’s objective was to analyze the epidemiological, clinical and pharmacological characteristics on patients with PAH and the impact on the survival rate.

Orlando Herrera
SPA 4003
December 6, 2016
INSUFICIENCIA CARDIACA
Noviembre de 2016

Pulmonary arterial hypertension in adult congenital heart disease
Impact and outcome
Data from GUTI-GUCH Register

Claudio Gabriel Morós, Marisa Pacheco Otero, Gianina Faliva, María del Carmen Rubio, Mariana López Daneri, Isabel Torres, Inés Abella, Álvaro Sosa Liprandi, Liliana Noemí Nicolosi, María Grippo

Introduction.
Adult congenital heart disease (ACHD) is one of fastest growing cardiology subgroups in latest years, due to early diagnosis and advances in surgical and endovascular treatment. It is estimated that 85-90% of patients with congenital heart disease will reach adulthood. The survival of these patients generates complications and sequelae that result in a higher rate of hospitalization and new surgeries, among other procedures.
It is estimated that 5 to 10% of patients with ACHD will develop pulmonary hypertension (PH) in their evolution and being currently the most frequent cause of pulmonary arterial hypertension (PAH) after connective tissue disease. Its occurrence is related to a worse prognosis for the patient.
The objective of the present study was to analyze the epidemiological, clinical and pharmacotherapy characteristics of patients with PAH and their impact on survival.

********************************************************************************************************
Hipertensión arterial pulmonar en cardiopatías congénitas del adulto
Impacto y resultados
Datos del Registro GUTI-GUCH

Claudio Gabriel Morós, Marisa Pacheco Otero, Gianina Faliva, María del Carmen Rubio, Mariana López Daneri, Isabel Torres, Inés Abella, Álvaro Sosa Liprandi, Liliana Noemí Nicolosi, María Grippo

Introducción
La cardiopatía congénita del adulto (CCA) es uno de los subgrupos de mayor crecimiento en los últimos años dentro de la cardiología, debido al diagnóstico precoz y al avance de los tratamientos quirúrgico y endovascular. Se calcula que el 85-90% de los pacientes con cardiopatías congénitas llegarán a la vida adulta. La sobrevida de estos pacientes genera complicaciones y secuelas que redundan en una mayor tasa de internaciones y nuevas cirugías, entre otros procedimientos.
Se estima que del 5 al 10% de los pacientes con CCA desarrollarán hipertensión pulmonar (HP) en su evolución siendo en la actualidad la causa más frecuente de hipertensión arterial pulmonar (HAP) después de las enfermedades del tejido conectivo
Su aparición se relaciona con peor pronóstico para el paciente.
El objetivo del presente trabajo fue analizar las características epidemiológicas, clínicas y de tratamiento farmacológico en pacientes con HAP y su impacto en la sobrevida.

Jorge Caceres

Spa 4003

INSUFICIENCIA CARDIACA

Insuf Card 2016;11 (3): 115-121

Pulmonary arterial hypertension in adult congenital heart diseases

Impact and outcome

Data from the GUTI-GUCH Registry

Claudio Gabriel Morós¹, Marisa Pacheco Otero², Gianina Faliva³, María del Carmen Rubio⁴, Mariana López Daneri⁵, Isabel Torres⁶, Inés Abella⁷, Álvaro Sosa Liprandi⁸, Liliana Noemí Nicolosi⁹, María Grippo¹⁰

Introduction

Adult congenital heart disease (ACHD) is one of the fastest growing cardiology subgroups in recent years, due to early diagnosis and advances in surgical and endovascular treatment. It is calculated that 85-90% of patients with congenital heart diseases reach adulthood. The survival of these patients generates complications and sequelae that contribute to a higher rate of hospital admissions and new surgeries, among other procedures^1,2.

It is estimated that 5 to 10% of patients with ACHD develop pulmonary hypertension (PH) during its progression^3,4, making it the most frequent cause of pulmonary arterial hypertension (PAH) after connective tissue diseases^5,6. Its’ appearance is related to a worse prognosis for the patient.

The objective of the present study was to analyze the epidemiological characteristics, clinical and pharmacological treatment in patients with PAH and their impact on survival.

Insuficiencia Cardiaca

Insuf Card 2016;11 (3): 115-121

Pulmonary arterial hypertension of congenital heart diseases in adults

Impact and results

Registry Data GUTI-GUCH

Claudio Gabriel Morós, Marisa Pacheco Otero, Gianina Faliva, María del Carmen Rubio, Mariana López Daneri, Isabel Torres, Inés Abella, Álvaro Sosa Liprandi, Liliana Noemí Nicolosi, María Grippo

Received: 6/25/2016

Accepted: 8/15/2016

Introduction

Adult congenital heart disease (ACHD) is one of the fastest-growing cardiology subgroups in recent years, due to early diagnosis and advances in surgical and endovascular treatment. It’s calculated that 85-90% of these patients with congenital heart disease will reach adulthood. The series of events that follow for these patients include complications, new surgeries and procedures.

It is estimated that 5 to 10% of patients with ACHD develop pulmonary hypertension (PH) in their development, in actuality it’s the most frequent cause for pulmonary arterial hypertension (PAH) after disease of the connective tissue. Its appearance in the patient signifies a much worst prognosis.

The objective of the study was to analyze the epidemiological characteristics clinical and pharmacological treatment in patients with pulmonary arterial hypertension (PAH) and their impact on survival

INSUFICIENCIA CARDIACA

Insuf Card 2016; 11 (3): 115-121

Pulmonary Arterial Hypertension in Adult Congenital heart Disease

Impact and Outcome

Data from the GUTI-GUCH Registry

Claudio Gabriel Morόs, Marisa Pacheco Otero, Gianina Faliya, María del Carmen Rubio, Mariana Lόpez Daneri, Isabel Torres, Inés Abella, Álvarado Sosa Liprandi, Liliana Noemí Nicolosi, María Grippo

Introduction

                  Adult congenital heart disease (ACHD) is one of cardiology’s fastest growing subgroup in recent years due to early diagnosis and advances in surgical and endovascular treatment. It has been calculated that 85-90% of patients diagnosed with congenital heart disease will reach adulthood. The survival of these patients generates complications and consequences that result in greater hospitalization rates and new surgeries among other procedures.

It is estimated that about 5-10% of patients with ACHD will develop pulmonary hypertension (PH) in its progression, making in the most frequent cause for pulmonary arterial hypertension (PAH), after connective tissue disease. Its emergence is related to a worse prognosis for the patient.

The objective of this study was to analyze the epidemiological characteristics, clinical, and pharmacological treatment of patients with PAH as well as their survival rate.

INSUFICIENCIA CARDIACA

Insuf Card 2016;11 (3): 115-121

Pulmonary arterial Hypertension in adult congenital heart disease

Impact and outcome

Data from the GUTI-GUCH Registry

Claudio Gabriel Moros, Marisa Pacheco Otero, Gianina Faliva, María del Carmen Rubio, Mariana López Daneri, Isabel Torres, Inés Abella, Álvaro Sosa Liprandi, Liliana Noemí Nicolosi, María Grippo

Introduction

Adult congenital heart disease (ACHD) is one of the fastest growing cardiology subgroups in recent years. Due to early diagnosis and advances in surgical and endovascular treatment.

It’s estimated that 85 – 90% of patients with congenital heart disease will reach adulthood. The survival of these patients generates complications and sequelae that result in a higher rate of hospitalizations and more surgeries, amid other complications.

It is estimated that 5 to 10% of patients with ACHD will develop pulmonary hypertension (PH) during its evolution, being currently the most frequent cause of pulmonary hypertension (PAH) after connective tissue diseases^5,6. Its appearance is related to a worse prognosis for the patient.

The purpose of the present study was to analyze the epidemiological characteristics, clinical and pharmaceutical treatments of patients with PAH and their consequences on survival.

INSUFICIENCIA CARDIACA

Insuf Card 2016;11 (3): 115-121

Pulmonary arterial hypertension in adult congenital heart diseases

Impact and outcome

Data from the GUTI-GUCH Registry

Claudio Gabriel Morós¹, Marisa Pacheco Otero², Gianina Faliva³, María del Carmen Rubio⁴, Mariana López Daneri⁵, Isabel Torres⁶, Inés Abella⁷, Álvaro Sosa Liprandi⁸, Liliana Noemí Nicolosi⁹, María Grippo¹⁰

Introduction

Adult congenital heart disease (ACHD) is one of the fastest growing cardiology subgroups in recent years, due to early diagnosis and advances in surgical and endovascular treatment. It is calculated that 85-90% of patients with congenital heart diseases reach adulthood. The survival of these patients generates complications and sequelae that contribute to a higher rate of hospital admissions and new surgeries, among other procedures^1,2.

It is estimated that 5 to 10% of patients with ACHD develop pulmonary hypertension (PH) during its progression^3,4, making it the most frequent cause of pulmonary arterial hypertension (PAH) after connective tissue diseases^5,6. Its’ appearance is related to a worse prognosis for the patient.

The objective of the present study was to analyze the epidemiological characteristics, clinical and pharmacological treatment in patients with PAH and their impact on survival.

Beverly James

Professor Allen

Spanish 4003

12/6/2016

INSUFICIENCIA CARDIACA

Insuf Card 2016; 11 (3): 115-121

                                     Pulmonary arterial hypertension in adult congenital heart disease 

                                                                        Impact and outcome 

                                                          Data from the GUTI-GUCH Registry

Claudio Gabriel Moros, Marisa Pacheco Otero, Gianina Faliva, Maria del Carmen Rubio,

Mariana Lopez Daneri, Isabel Torres, Ines Abella, Alvaro Sosa Liprandi,

Liliana Noemi Nicolosi, Maria Grippo

 Introduction 

 The adult congenital heart disease (ACHD) is one of the fastest growing subgroups within cardiology in the last years due to precocious diagnosis and the progress of surgical and endovascular treatments. It is calculated that 85-90% of patients with congenital heart disease will reach adulthood. The sequelae and complications generated by the survival of these patients result in higher rates of hospitalizations, new surgeries and other proceedings.

Currently being the most frequent cause of pulmonary arterial hypertension (PAH) after the connective tissue disease, it is estimated that throughout the progression of ACHD, 5-10% of its patients will develop pulmonary hypertension (PH). Its occurrence is related to a worst prognosis.

The objective of the present study was to analyze the epidemiological characteristics, clinical and pharmacological treatments in patients with PAH and their impact on survival.

INSUFICIENCIA CARDIACA                                                                                          ISSN 1850-1044

Insuf Card 2016;11 (3): 115-121                                                                                   2016 Silver Horse

Pulmonary Arterial Hypertension in Adult Congenital Heart Disease

Impact and Outcomes

Data from the GUTI-GUCH Registry

Claudio Gabriel Morós, Marisa Pacheco Otero, Gianina Faliva, María del Carmen Rubio,

Mariana López Daneri, Isabel Torres, Inés Abella, Álvaro Sosa Liprandi,

Liliana Noemí Nicolosi, María Grippo

Introduction

Adult congenital heart disease (ACHD) is one of the fastest-growing cardiology subgroups in recent years, due to the early diagnosis and advances in surgical and endovascular treatment. It is estimated that 85-90% of patients with congenital heart disease reach adult age. The survival of these patients generate complications and sequels that result in high rates of hospitalizations and new surgeries, among other procedures.

It is estimated that from 5 to 10% of the patients with ACHD develop pulmonary hypertension (PH) during their progression, which in reality the most frequent case of pulmonary arterial hypertension (PAH) after the diseases of connective tissue. Their appearance is related to a worse prognosis for the patient.

The objective of the present study was to analyze the epidemiologic characteristics, clinical, and pharmacological treatment in patients with PAH and its impact on their survival.